PA
YMAB

Perceptive Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Perceptive Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-212,018
Closed -$3.06M – 111
2022
Q3 		$3.06M Hold
212,018
– – 0.09% 93
2022
Q2 		$3.21M Buy
+212,018
New +$2.47M 0.1% 88
2020
Q3 		– Sell
-355,366
Closed -$15.4M – 143
2020
Q2 		$15.4M Sell
355,366
-167,114
-32% -$6.32M 0.25% 70
2020
Q1 		$12.1M Sell
522,480
-39,757
-7% -$1.15M 0.31% 56
2019
Q4 		$17.6M Sell
562,237
-292,703
-34% -$8.66M 0.35% 52
2019
Q3 		$22.3M Buy
+854,940
New +$21.8M 0.6% 41

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Perceptive Advisors's YMAB Position: Q4 2022 in Review

Perceptive Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q4 2022, closing a stake of 212,018 shares — an estimated $3.06M sold.

Perceptive Advisors first reported a position in YMAB in Q3 2019 and held it in 6 quarters. The position peaked at $22.3M in Q3 2019. 91 funds tracked by Wall St. Rank hold YMAB as of Q4 2022.

  • Perceptive Advisors reported no remaining Y-mAbs Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Perceptive Advisors sold 212,018 Y-mAbs Therapeutics shares in Q4 2022, an estimated $3.06M.
  • Perceptive Advisors first reported a position in Y-mAbs Therapeutics in Q3 2019 and held it in 6 quarters.
  • Perceptive Advisors's Y-mAbs Therapeutics position peaked at $22.3M in Q3 2019.
  • 91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2022.

Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.